<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-07-21T14:26:58Z</responseDate><request verb="GetRecord" identifier="oai:repisalud.isciii.es:20.500.12105/6672" metadataPrefix="mets">https://repisalud.isciii.es/rest/oai/request</request><GetRecord><record><header><identifier>oai:repisalud.isciii.es:20.500.12105/6672</identifier><datestamp>2024-11-28T16:28:38Z</datestamp><setSpec>com_20.500.12105_19604</setSpec><setSpec>com_20.500.12105_2051</setSpec><setSpec>com_20.500.12105_15322</setSpec><setSpec>col_20.500.12105_19605</setSpec><setSpec>col_20.500.12105_16938</setSpec></header><metadata><mets xmlns="http://www.loc.gov/METS/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="&#xa;&#x9;&#x9;&#x9;&#x9;DSpace_ITEM_20.500.12105-6672" TYPE="DSpace ITEM" PROFILE="DSpace METS SIP Profile 1.0" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd" OBJID="&#xa;&#x9;&#x9;&#x9;&#x9;hdl:20.500.12105/6672">
   <metsHdr CREATEDATE="2026-07-21T16:26:58Z">
      <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
         <name>Repisalud</name>
      </agent>
   </metsHdr>
   <dmdSec ID="DMD_20.500.12105_6672">
      <mdWrap MDTYPE="MODS">
         <xmlData xmlns:mods="http://www.loc.gov/mods/v3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
            <mods:mods xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Martinez-Lopez, Maria</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Soto, Manuel</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Iborra, Salvador</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">author</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Sancho, David</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Ministerio de Economía, Industria y Competitividad (España)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Ministerio de Educación, Cultura y Deporte (España)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Centro Nacional de Investigaciones Cardiovasculares Carlos III (España)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Agencia Estatal de Investigación (España)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Comunidad de Madrid (España)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Instituto de Salud Carlos III</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fondation ACTERIA (Acting on European Research in Immunology and Allergology)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Atresmedia</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fundación La Marató TV3</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Unión Europea. Comisión Europea</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Unión Europea. Comisión Europea. European Research Council (ERC)</mods:namePart>
               </mods:name>
               <mods:name>
                  <mods:role>
                     <mods:roleTerm type="text">funder</mods:roleTerm>
                  </mods:role>
                  <mods:namePart>Fundación ProCNIC</mods:namePart>
               </mods:name>
               <mods:extension>
                  <mods:dateAccessioned encoding="iso8601">2018-11-22T08:10:51Z</mods:dateAccessioned>
               </mods:extension>
               <mods:extension>
                  <mods:dateAvailable encoding="iso8601">2018-11-22T08:10:51Z</mods:dateAvailable>
               </mods:extension>
               <mods:originInfo>
                  <mods:dateIssued encoding="iso8601">2018</mods:dateIssued>
               </mods:originInfo>
               <mods:identifier type="none"/>
               <mods:identifier type="citation">Front Microbiol. 2018; 9:883</mods:identifier>
               <mods:identifier type="doi">10.3389/fmicb.2018.00883</mods:identifier>
               <mods:identifier type="issn">1664-302X</mods:identifier>
               <mods:identifier type="journal">FRONTIERS IN MICROBIOLOGY</mods:identifier>
               <mods:identifier type="pubmedID">29867798</mods:identifier>
               <mods:identifier type="uri">http://hdl.handle.net/20.500.12105/6672</mods:identifier>
               <mods:abstract>Protozoan parasites of the Leishmania genus are the causative agents of leishmaniasis, a group of neglected tropical diseases whose clinical manifestations vary depending on the infectious Leishmania species but also on host factors. Recognition of the parasite by host myeloid immune cells is a key to trigger an effective Leishmania-specific immunity. However, the parasite is able to persist in host myeloid cells by evading, delaying and manipulating host immunity in order to escape host resistance and ensure its transmission. Neutrophils are first in infiltrating infection sites and could act either favoring or protecting against infection, depending on factors such as the genetic background of the host or the parasite species. Macrophages are the main host cells where the parasites grow and divide. However, macrophages are also the main effector population involved in parasite clearance. Parasite elimination by macrophages requires the priming and development of an effector Th1 adaptive immunity driven by specific subtypes of dendritic cells. Herein, we will provide a comprehensive outline of how myeloid cells regulate innate and adaptive immunity against Leishmania, and the mechanisms used by the parasites to promote their evasion and sabotage. Understanding the interactions between Leishmania and the host myeloid cells may lead to the development of new therapeutic approaches and improved vaccination to leishmaniases, an important worldwide health problem in which current therapeutic or preventive approaches are limited.</mods:abstract>
               <mods:language>
                  <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
               </mods:language>
               <mods:accessCondition type="useAndReproduction"/>
               <mods:subject>
                  <mods:topic>Myeloid cell</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Leishmania</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Immune escape</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Neutrophils</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Macrophages</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>Dendritic cells</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>NEUTROPHIL EXTRACELLULAR TRAPS</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>CD8(+) T-CELLS</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>MACROPHAGE IL-12 PRODUCTION</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>TYROSINE-PHOSPHATASE SHP-1</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>NITRIC-OXIDE SYNTHASE</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>HUMAN DENDRITIC CELLS</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>PROTEIN-KINASE-C</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>KINETOPLASTID MEMBRANE PROTEIN-11</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>DONOVANI PROMASTIGOTES EVADE</mods:topic>
               </mods:subject>
               <mods:subject>
                  <mods:topic>SUSCEPTIBLE BALB/C MICE</mods:topic>
               </mods:subject>
               <mods:titleInfo>
                  <mods:title>Leishmania Hijacks Myeloid Cells for Immune Escape</mods:title>
               </mods:titleInfo>
               <mods:genre>journal article</mods:genre>
            </mods:mods>
         </xmlData>
      </mdWrap>
   </dmdSec>
   <amdSec ID="FO_20.500.12105_6672_1">
      <techMD ID="TECH_O_20.500.12105_6672_1">
         <mdWrap MDTYPE="PREMIS">
            <xmlData xmlns:premis="http://www.loc.gov/standards/premis" xsi:schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
               <premis:premis>
                  <premis:object>
                     <premis:objectIdentifier>
                        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
                        <premis:objectIdentifierValue>https://repisalud.isciii.es/bitstreams/83ad0129-a824-46b5-bf0c-0cfd0b28e73c/download</premis:objectIdentifierValue>
                     </premis:objectIdentifier>
                     <premis:objectCategory>File</premis:objectCategory>
                     <premis:objectCharacteristics>
                        <premis:fixity>
                           <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
                           <premis:messageDigest>533055dbcfe8ab7c5811bd094d164f00</premis:messageDigest>
                        </premis:fixity>
                        <premis:size>2547803</premis:size>
                        <premis:format>
                           <premis:formatDesignation>
                              <premis:formatName>application/pdf</premis:formatName>
                           </premis:formatDesignation>
                        </premis:format>
                     </premis:objectCharacteristics>
                     <premis:originalName>LeishmaniaHijacksMyeloidCells_2018.pdf</premis:originalName>
                  </premis:object>
               </premis:premis>
            </xmlData>
         </mdWrap>
      </techMD>
   </amdSec>
   <amdSec ID="FT_20.500.12105_6672_4">
      <techMD ID="TECH_T_20.500.12105_6672_4">
         <mdWrap MDTYPE="PREMIS">
            <xmlData xmlns:premis="http://www.loc.gov/standards/premis" xsi:schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
               <premis:premis>
                  <premis:object>
                     <premis:objectIdentifier>
                        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
                        <premis:objectIdentifierValue>https://repisalud.isciii.es/bitstreams/7f60f13e-e048-4e7e-b867-18e7034ff6a0/download</premis:objectIdentifierValue>
                     </premis:objectIdentifier>
                     <premis:objectCategory>File</premis:objectCategory>
                     <premis:objectCharacteristics>
                        <premis:fixity>
                           <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
                           <premis:messageDigest>43554ef0fee2b99be52d0ee6cb4b8ae8</premis:messageDigest>
                        </premis:fixity>
                        <premis:size>109271</premis:size>
                        <premis:format>
                           <premis:formatDesignation>
                              <premis:formatName>text/plain</premis:formatName>
                           </premis:formatDesignation>
                        </premis:format>
                     </premis:objectCharacteristics>
                     <premis:originalName>LeishmaniaHijacksMyeloidCells_2018.pdf.txt</premis:originalName>
                  </premis:object>
               </premis:premis>
            </xmlData>
         </mdWrap>
      </techMD>
   </amdSec>
   <fileSec>
      <fileGrp USE="ORIGINAL">
         <file ID="BITSTREAM_ORIGINAL_20.500.12105_6672_1" MIMETYPE="application/pdf" SEQ="1" SIZE="2547803" CHECKSUM="533055dbcfe8ab7c5811bd094d164f00" CHECKSUMTYPE="MD5" ADMID="FO_20.500.12105_6672_1" GROUPID="GROUP_BITSTREAM_20.500.12105_6672_1">
            <FLocat LOCTYPE="URL" xlink:type="simple" xlink:href="https://repisalud.isciii.es/bitstreams/83ad0129-a824-46b5-bf0c-0cfd0b28e73c/download"/>
         </file>
      </fileGrp>
      <fileGrp USE="TEXT">
         <file ID="BITSTREAM_TEXT_20.500.12105_6672_4" MIMETYPE="text/plain" SEQ="4" SIZE="109271" CHECKSUM="43554ef0fee2b99be52d0ee6cb4b8ae8" CHECKSUMTYPE="MD5" ADMID="FT_20.500.12105_6672_4" GROUPID="GROUP_BITSTREAM_20.500.12105_6672_4">
            <FLocat LOCTYPE="URL" xlink:type="simple" xlink:href="https://repisalud.isciii.es/bitstreams/7f60f13e-e048-4e7e-b867-18e7034ff6a0/download"/>
         </file>
      </fileGrp>
   </fileSec>
   <structMap LABEL="DSpace Object" TYPE="LOGICAL">
      <div TYPE="DSpace Object Contents" ADMID="DMD_20.500.12105_6672">
         <div TYPE="DSpace BITSTREAM">
            <fptr FILEID="BITSTREAM_ORIGINAL_20.500.12105_6672_1"/>
         </div>
      </div>
   </structMap>
</mets></metadata></record></GetRecord></OAI-PMH>